Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
March 22 2017 - 4:01PM
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced that
it has commenced an underwritten public offering of 5,000,000
shares of its common stock. Bellicum expects to grant the
underwriters of the offering a 30-day option to purchase up to an
additional 750,000 shares of its common stock at the public
offering price, less the underwriting discounts and commissions.
All shares of common stock to be sold in the offering will be
offered by Bellicum. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Citigroup and Jefferies are acting as lead
book-running managers for the offering.
The securities described above are being offered by
Bellicum pursuant to a shelf registration statement filed by
Bellicum with the Securities and Exchange Commission (SEC), which
was declared effective on February 1, 2016. A preliminary
prospectus supplement related to the offering will be filed with
the SEC and will be available for free on the SEC’s website at
http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus related to this offering, when
available, may be obtained from: Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at (800) 831-9146; or Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388, or by e-mail at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Bellicum Pharmaceuticals,
Inc.
Bellicum is a clinical stage biopharmaceutical
company focused on discovering and developing cellular
immunotherapies for cancers and orphan inherited blood disorders.
Bellicum is using its proprietary Chemical Induction of
Dimerization (CID) technology platform to engineer and control
components of the immune system. Bellicum is developing
next-generation product candidates in some of the most important
areas of cellular immunotherapy, including hematopoietic stem cell
transplantation (HSCT), and CAR T and TCR cell therapies. Bellicum
is based in Houston, Texas.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. This press
release may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “expected,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the completion and size of its public offering. Various factors may
cause differences between Bellicum’s expectations and actual
results, including risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions
related to the public offering, as well as those discussed in
greater detail in Bellicum’s filings with the SEC, including
without limitation in its Form 10-K for the year ended December 31,
2016. Any forward-looking statements that are made in this press
release speak only as of the date of this press release. Bellicum
assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024